LIVE WEBINAR

Unlocking ADC Resistance: Innovative Resistant Cell Line Platforms and Screening Strategies

Join ICE Bioscience for an exclusive webinar on conquering one of the most critical challenges in modern oncology: drug resistance in ADC therapies.

Antibody-drug conjugates and their highly potent payloads, such as Topoisomerase I inhibitors including DXd and SN-38, as well as Tubulin inhibitors such as MMAE, have revolutionized cancer treatment. However, acquired resistance remains a significant clinical hurdle.

In this comprehensive webinar, ICE Bioscience will unveil its cutting-edge ADC and Payload Resistant Cell Line Screening Platform. The session will walk through robust methodologies for generating clinically relevant resistant models, including both in vitro drug-induced resistance and genetic editing approaches such as ABCB1/ABCG2 overexpression. These validated cell lines are designed to support next-generation inhibitor discovery, novel mechanism-of-action exploration, and high-throughput combinatorial screening.

Key Topics

1. The Generation of Robust Resistant Cell Lines
               Discover ICE Bioscience’s workflow for building drug-resistant models, including rigorous in vitro induction processes and genetic editing strategies, backed by phenotypic and functional validations such as growth curves, STR profiling, and stability tests.

2. Deep Dive into MoA
               Explore the multi-omics landscape of drug resistance. Using RNA-seq and WES bioinformatic analyses, the webinar will dissect key resistance mechanisms including drug efflux pumps such as P-gp and BCRP, payload target mutations, and DNA Damage Response alterations involving replisome, cell cycle checkpoints, and HR/FA repair pathways.

3. Validation of Multidrug Resistance
               Learn how specific resistant strains, such as DXd- or SN-38-resistant lines, exhibit cross-resistance to a spectrum of compounds including Topotecan, Niraparib, and Belotecan, providing a crucial matrix for compound evaluation.

4. Cell Panel-Based Screening: Overcoming Resistance & Finding Synergy
               See how extensive resistant cell panels and specialized cancer cell panels can support drug discovery programs. The session will present a case study in which 120+ drug pairs were screened, successfully identifying synergistic combinations such as pairing DDR targets including ATR/CHK1 inhibitors with ADCs to overcome established resistance.

What You Will Gain

• Actionable Insights: Understand the intricate biological pathways driving ADC and payload resistance.

• Accelerated R&D: Learn how to access 39+ ready-to-use resistant cell line screening models covering major targets such as HER2, TROP2, and c-Met across gastric, breast, colorectal, and ovarian cancers.

• Data-Driven Confidence: Discover how comprehensive multi-omics background data, including RNA-seq and WES, can guide pipeline decisions.

• Customized Screening Solutions: Gain strategies for utilizing flexible, high-quality cell panel platforms for fast-turnaround combinatorial and single-agent efficacy screening.

Join us to learn how innovative resistant cell line platforms and screening strategies can help accelerate ADC discovery, reveal resistance mechanisms, and support the development of rational combination approaches.

Copyright © 2026 ICE Bioscience